Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]

The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

The social worker in the Pediatric Multiple Sclerosis Clinic at Children's Hospital of Philadelphia talked about depression and suicidality rates in pediatric patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The postdoctoral researcher in the department of neurology at John Hopkins School of Medicine talked about indole-3-lactate as a signaling molecule in the gut-brain axis and its potential as a treatment for MS. [WATCH TIME: 5 minutes]

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

A group of experts in the care of patients with neurological conditions—Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath; Andrew Solomon, MD; Anne H. Cross, MD; Anthony Feinstein, MPhil, PhD, FRCP; Brian G. Weinshenker, MD, FRCP—shared their perspectives on hot topics of treatment and management in multiple sclerosis from the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting.

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, discussed the challenges in understanding and measuring fatigue in patients with multiple sclerosis.

As a recap from CMSC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

At CMSC 2023, the professor of psychiatry at the University of Toronto talked about cognitive behavioral therapy and mindfulness-based therapy that shows promise in alleviating fatigue in multiple sclerosis, offering potential treatment options. [WATCH TIME: 5 minutes]

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

The professor of neurology at the University of Virginia discussed the progress made in recognizing and diagnosing neuromyelitis optica spectrum disorder through the discovery of specific monoclonal antibodies. [WATCH TIME: 5 minutes]

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.

The professor of neurology at Oregon Health & Science University talked about a study on a modified low-fat diet intervention and its effects on fatigue in patients with multiple sclerosis over a 16-week period at CMSC 2023. [WATCH TIME: 8 minutes]

Patients with multiple sclerosis who presented with high-stress maintained their stress management practice through later protocol sessions, according to a study a recent study.

At the 2023 CMSC Annual Meeting, Christopher C. Hemond, MD, assistant professor of neurology at UMass Chan Medical School, provided an overview of his study on mindfulness-based stress reduction in patients with MS using MRI and patient outcomes.

The professor of neurology at Washington University School of Medicine discussed progressive multiple sclerosis and the need for targeted therapies to address the progression and associated challenges. [WATCH TIME: 5 minutes]

In the 2023 Donald Paty Lecture, speaker Darin Okuda presented novel MRI methods that might help determine whether MS lesions have potential for future remyelination.

At CMSC 2023, the associate professor of neurological sciences at the University of Vermont in Burlington talked about data surrounding multiple sclerosis diagnosis and misdiagnosis, suggesting the need for the development of diagnostic biomarkers. [WATCH TIME: 5 minutes]

At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]

Most patients completed at least 3 years of treatment, with no new safety signals observed and a treatment discontinuation rate of 5.3%.

The first results from a phase 2 study frexalimab (SAR441344; Sanofi), in relapsing multiple sclerosis have shown promise for the anti-CD40L antibody.

Although the CDC has declared the public health emergency for the COVID-19 pandemic over, patients with multiple sclerosis and other conditions are still in need of guidance.

Using the Modified Fatigue Impact Scale, patients either forced to exercise or who volunteered saw significant improvements over a 12-week period.